Deborah Davis, Non-Executive Chair

Deborah has extensive global experience in platform business models, software, fintech, telecoms and e-commerce businesses.

After completing her undergraduate studies in Australia, Deborah spent over two decades in CEO and European and global senior executive roles including at internet platform businesses PayPal and eBay, and technology companies Symantec and Verizon.

Deborah currently holds non-executive director and board committee positions at the following institutions: Lloyds Banking Group/Scottish Widows Insurance,, International Personal Finance plc, IDEX Biometrics ASA, Norway and, the Institute of Directors UK. Her previous Board experience includes Which? Ltd and private equity based i.e. Digital. Deborah is a trustee of the Southern African Conservation Trust.

Deborah is a Chartered Director and a Fellow of the Institute of Directors. She holds a Bachelor of Applied Science (Electronics) Honours degree from the University of Melbourne and a Sloan Master’s in Science (Management) with distinction from London Business School.

Ryan Keeling, Chief Executive Officer 

Ryan is an expert in the commercialisation of diagnostics and associated technology, with over 14 years’ experience in the field.

Ryan has led the development and commercialisation of the Group’s technology, including its proprietary data lake. Ryan has played a pivotal role in the Group’s technological and strategic development, previously acting as its chief operating officer until June 2018. As CIO, Ryan is responsible for driving the Company’s product innovation, with a near term focus on the development of DXRX. Prior to joining Diaceutics in 2009, Ryan spent eight years as a software engineer for Aepona Limited, providing network infrastructure and related services to telecommunications operators.

 Ryan holds a software engineering degree from Queens University, Belfast. Ryan is seen as a thought leader in the field of diagnostic commercialisation and data integration speaking at precision medicine and healthcare data conferences globally.

Peter Keeling, Founder

Peter has over 33 years’ experience as a leader, entrepreneur and strategist in the Pharma industry. He has led international companies and teams with a focus on novel business models and product launches, including therapies, diagnostics and FMCG products.

Peter started his career as Distribution Manager at American Monitor Corporation where he oversaw the distribution of diagnostic reagents and equipment globally. He subsequently spent a total of 11 years leading projects in both operational and strategic roles at the therapy division of the Wellcome Foundation, including as sales manager for the Pharma business in North and West Africa (four years), Commercial Director for a joint venture with Wellcome Indonesia, and as brand director at global product level for Wellcome’s antiviral franchise. Wellcome was merged with Glaxo in 1995. Subsequently, he founded and was chief executive officer of Diagnology Inc, a US/Irish based diagnostics company which specialised in the development and commercialisation of tests for sexually transmitted diseases. Peter has led Diaceutics from its inception in 2005 to become a leader in precision testing commercialisation which currently supports the principal market biomarker programmes for the world’s largest Pharma companies.

Peter holds a degree in business administration from Queens University Belfast, a Master’s degree in European Marketing from Buckingham University Business School and spent an academic year as a Visiting Fellow at MIT’s Sloan business school in 1994 where he led a multi-corporation US think tank designed to look at disruptive models in future patient health for the Pharma industry. Peter has published several peer reviewed papers on precision medicine and is a respected speaker at Precision Medicine events around the world.

Nick Roberts FCA, Chief Financial Officer

Nick is a highly experienced senior finance professional with a track record of managing and developing finance functions and governance structures in high growth AIM-quoted healthcare and technology companies with global customer bases.

Prior to his appointment to Diaceutics PLC, he was Head of Group Reporting at AIM-quoted Ergomed PLC, a full-service pharmacovigilance and specialist clinical trial service provider to the pharma and biotechnology industries. During his tenure, Nick developed and managed the day-to-daygroup finance reporting requirements for Ergomed plc and oversaw the roll-out of several governance framework and reporting projects, including the financial integration oftwo US business acquisitions. Prior to this, he was Group Financial Controller at AIM-quoted Ceres Power Holdingsplc, a fuel cell and electrochemical technology development company, leading the development of the finance function to accommodate a period of considerable commercial and financial growth over four years.

Nick is a Fellow Chartered Accountant with the Institute of Chartered Accountants in England and Wales (ICAEW) and holds a bachelor’s degree in Accounting and Finance from the University of Southampton.

Michael Wort, Non-Executive Director

Having trained as a microbiologist, Mike brings over 46 years’ experience working with life science companies across the healthcare sector. Initially working with three of the top ten global Pharma companies in a variety of sales, marketing and research positions, he was appointed investor relations manager of Wellcome Plc and was actively involved in the global communications programme for the £2.4 bn secondary offering of Wellcome Plc shares by the Wellcome Trust, which enabled him to develop working relationships with leading City stakeholder groups  in the life sciences industry.

Mike was a founding partner in the first specialist communications agency to support the emerging biotechnology industry with City communications. Apart from a period when he was involved as CEO during the privatisation of the Bulgarian Pharma industry his career has been devoted to working with start-up and growing SMEs to maximise their potential for growth.

Graham Paterson, Non-Executive Director

Graham is a seasoned business leader and Non-Executive Director with a wealth of expertise spanning investment, software, and data analytics. As a founding partner of SL Capital Partners LLP, he served as a partner and board member until 2010. In 2013, Graham co-founded TopQ Software Limited, a technology company specializing in software for the private equity sector, later acquired by eVestment Inc (now part of NASDAQ Inc) in 2015, where he held a directorship in their private markets data and analytics division until early 2018. Currently, Graham serves as a non-executive director and chairman of the audit committee for Baillie Gifford US Growth Trust plc and Invesco Perpetual UK Smaller Companies Trust Plc. He also chairs the boards of Mobeus Income and Growth 4 VCT plc, Datactics Limited, and Substantive Research Limited. Graham is a Chartered Accountant, a member of the Institute of Chartered Accountants of Scotland, and holds an Honours degree in Economics and Management from the University of St. Andrews.